Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01023958 · ClinicalTrials.gov registry record · Phase 2
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01023958 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 50 participants.
The verdict
NCT01023958, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the efficacy and safety of BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer after failure of first line or adjuvant/neoadjuvant chemotherapy.
Interventions
- DRUG BI 6727, IV infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-11-19 |
| Est. Completion | 2011-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01023958
The ClinicalTrials.gov registry entry for NCT01023958 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 6727, IV infusion is the first listed.
NCT01023958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01023958 about?
NCT01023958 is a clinical study titled "Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer". The primary objective of this trial is to evaluate the efficacy and safety of BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer after failure of first line or adjuvant/neoadjuvant chemotherapy.
What is the current status of trial NCT01023958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2009-11-19. Estimated completion is 2011-09-19.
What interventions are being tested in trial NCT01023958?
The interventions under investigation include: BI 6727, IV infusion (DRUG).
Who is sponsoring clinical trial NCT01023958?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.